| Board of Regents, The University of Texas System Patent applications |
| Patent application number | Title | Published |
|---|
| 20220296511 | COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS TO TREAT LUNG DISEASE - In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from:
| 09-22-2022 |
| 20220296102 | MINIMALLY INVASIVE COLLECTION PROBE AND METHODS FOR THE USE THEREOF - Method and devices are provided for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis. In certain aspects, devices of the embodiments allow for minimally invasive collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis. | 09-22-2022 |
| 20220294450 | MAGNETOELECTRIC INVERTER - A magneto-electric (ME) inverter includes two anti-ferromagnetic spin orbit read (AFSOR) circuit elements, each AFSOR circuit element has a CMOS inverter; and an AFSOR device with a ME base layer; a semiconductor channel layer on the ME base layer and comprising a source terminal and a drain terminal, where the source terminal is coupled to an output of the CMOS inverter; and a gate electrode on the semiconductor channel layer. The gate electrode of a second AFSOR device of the two AFSOR circuit elements is coupled to the drain terminal of a first AFSOR device of the two AFSOR circuit elements. | 09-15-2022 |
| 20220294449 | MAGNETOELECTRIC MAJORITY GATE DEVICE - A magneto-electric (ME) majority gate device includes a conducting device and a plurality of ME transistors coupled to the conducting device. In one implementation, the plurality of ME transistors include a ME AND gate device with downward interface polarization, a ME-transmission gate device with downward interface polarization, and a ME-XNOR gate device. In another implementation, the plurality of ME transistors is five single-input ME-FETs. | 09-15-2022 |
| 20220294448 | MAGNETOELECTRIC XNOR LOGIC GATE DEVICE - A magneto-electric (ME) XNOR logic gate device includes a conducting device; and a ME-FET coupled to the conducting device. The ME-FET can be formed of a split gate; a first gate terminal coupled to a first portion of the split gate for receiving a first input signal; a second gate terminal coupled to a second portion of the split gate for receiving a second input signal; a source terminal coupled to a ground line; and a drain terminal coupled to the conducting device. | 09-15-2022 |
| 20220288121 | CELL CRYOPRESERVATION MEDIUM - Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant. | 09-15-2022 |
| 20220268784 | USING MASS SPECTROMETRY TO IDENTIFY ENDOMETRIOSIS TISSUE - In a general aspect, methods and devices are provided for using mass spectrometry to identify endometriosis. In some aspects, a fixed or discrete volume of a solvent is applied to a tissue site including possible endometriosis tissue. The applied solvent is collected to obtain a liquid sample. The liquid sample is subjected to mass spectrometry analysis. The liquid sample is collected from a tissue site in vivo during a medical procedure. The mass spectrometry data are analyzed to identify whether the tissue site comprises endometriosis. | 08-25-2022 |
| 20220268707 | Phosphorous-Based Sensors For Detection Of Multiple Solvents - Embodiments of the present disclosure pertain to methods of monitoring an environment for the presence of a solvent by: (i) exposing the environment to a luminescent compound, where the relative luminescence emission intensity of the luminescent compound changes upon interaction with the solvent; and (ii) monitoring a change in the relative luminescence emission intensity of the luminescent compound, where the absence of the change indicates the absence of the solvent from the environment, and where the presence of the change indicates the presence of the solvent in the environment. The luminescent compounds include a phosphorous atom with one or more carboxyl groups, where the carboxyl groups are coordinated with one or more metallic ions (e.g., lanthanide ions and yttrium ions). The present disclosure also pertains to sensors for monitoring an environment for the presence of a solvent, where the sensors include one or more of the aforementioned luminescent compounds. | 08-25-2022 |
| 20220265847 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER - Aspects of the disclosure relate to a method for treating EGFR-mutant non-small-cell lung cancer (NSCLC) in a patient comprising administering a CD70 targeting molecule to the patient. Further aspects of the disclosure relate to a method for treating an epithelial-to-mesenchymal transition (EMT)-positive NSCLC in a patient comprising administering a CD70-targeting molecule to the patient. | 08-25-2022 |
| 20220265726 | USE OF VETO CELLS FOR THE TREATMENT OF SICKLE CELL DISEASE - A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation. | 08-25-2022 |
| 20220262561 | Self-Shielded High Frequency Inductor - In one aspect, described is a magnetic-core inductor design approach that leverages NiZn ferrites with low loss at RF, distributed gaps and field balancing to achieve improved performance eat tens of MHz and at hundreds of watts and above. Also described is an inductor design which achieves “self-shielding” in which the magnetic field generated by the element is wholly contained within the physical volume of the structure rather than extending into space as a conventional air-core inductor would. This approach enables significant reductions of system enclosure volume and improvements in overall system efficiency. | 08-18-2022 |
| 20220260062 | THERMALLY-POWERED POLYMER FIBER TENSILE ACTUATORS AND ARTICLES INCLUDING SAME - Actuators (artificial muscles) comprising twisted polymer fibers generate tensile actuation when powered thermally. In some embodiments, the thermally-powered polymer fiber tensile actuator can be incorporated into an article, such as a textile or garment. | 08-18-2022 |
| 20220259774 | SHEATH-RUN ARTIFICIAL MUSCLES AND METHODS OF USE THEREOF - Sheath-run artificial muscles (or SRAMs) are described in which the dimensional changes and/or modulus changes of a sheath on the surface of a twisted or coiled host yarn or fiber drives torsional and tensile actuation. The sheath-core artificial muscle includes a sheath on a coiled core yarn or fiber that has inserted twist, in which the sheath does not include a yarn, the coiled core yarn or fiber includes a core yarn or fiber, the sheath can change volume, modulus, or a combination thereof when actuated by an influence source to drive actuation, and the influence source is selected from a group consisting of absorption processes, desorption processes, changes in temperature, changes in external pressure, changes in a magnetic field, changes in an electric field, exposures to actinic radiation, electrochemical charge and discharge, chemical reactions, and combinations thereof. These sheath-run muscles can be used for diverse applications, such as robots, robotic devices, energy harvesters, muscles that enable electrical energy harvesting, comfort-adjusting textiles, comfort-adjusting clothing, bio-powered intelligent muscles that control the release of drugs, muscles for appropriate drug delivery, intelligent muscles that sense their environment and actuate in response, muscles for artificial limbs and orthotic gloves, muscles for haptic applications, muscles that can perform in extreme environments, and muscles for intelligent solar panel positioning. | 08-18-2022 |
| 20220257603 | COMBINATION THERAPY FOR TREATING MTAP-DEFICIENT TUMORS - Provided herein are methods of treating patients with a combination of an anti-folate agent and an A2BR antagonist. Also provided are methods of treating patients with a combination of an anti-folate agent and an immune checkpoint inhibitor. The patients are selected for treatment based on having an MTAP-deficient cancer. | 08-18-2022 |
| 20220257601 | INHIBITORS OF PRC1 FOR TREATMENT OF CANCER - Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L 1 inhibitors, or CTLA-4 inhibitors. | 08-18-2022 |
| 20220249033 | COMPUTED TOMOGRAPHY (CT) IMAGING ARTIFACT REDUCTION TECHNIQUE MAKING USE OF TILTED SCANS - Apparatus and methods for imaging a region of a subject comprising an artifact. In certain embodiments, the apparatus and methods utilize computed tomography (CT) scans obtained at two different angles to image a region posterior to an artifact. | 08-11-2022 |
| 20220242854 | Small molecule inducers of autophagy - Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity. | 08-04-2022 |
| 20220235348 | CRISPR METHODS FOR TREATING CANCERS - Methods for reversing one or more mutations in the telomerase (TERT) promoter are provided and may be used to treat a cancer. In some embodiments, programmable base editing (PBE) is used to correct a mutated TERT promoter (e.g., −124 C>T, −228C>T, or −250C>T to −124 C, −228C, or −250C, respectively) by using a single guide (sg) RNA-guided and deactivated | 07-28-2022 |
| 20220233594 | TARGETING OTUB1 IN IMMUNOTHERAPY - The present disclosure provides methods for generating Otub 1 deficient T cells and natural killer (NK) cells and compositions comprising engineered T cells expressing a reduced amount of Otub 1. Further provided are methods of treating cancer comprising administering the Otub 1 deficient T cells and/or NK cells to a subject in need thereof. | 07-28-2022 |
| 20220231629 | SYSTEM FOR ESTIMATING A NUMBER OF SHORTED TURNS IN A PERMANENT MAGNET SYNCHRONOUS MOTOR WITH INTER TURN SHORT CIRCUIT FAULTS - A system and method estimate the fault severity index and consequently the number of shorted turns in permanent magnet motors (PMSM) with inter turn short circuit fault (ITSC). In this method, the machine is excited with DC current at stand still conditions to obtain the winding resistance seen by the d-axis of the machine. The estimated d-axis resistance contains useful information pertaining to the fault severity index, and is used to extract the fault severity index and the number of shorted turns in the faulty motor. The method enables the estimation of fault severity index without complex modeling with different machine prototypes, or FEA models to analyze the relationship between machine currents and short circuit current. To enhance the accuracy of the estimation method, this disclosure addresses issues associated with inverter non-linearity effects such as distortion voltage due to dead time effects and voltage drops across the switching devices. | 07-21-2022 |
| 20220226321 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN - The disclosure provides methods and compositions for inhibiting pain and comorbid cognitive deficits by administering a MNK inhibitor to a subject in need thereof. Also provided are methods of using the inhibitor in combination with other pain therapies. | 07-21-2022 |
| 20220218851 | COMPOUNDS AND METHODS FOR IMAGING IMMUNE ACTIVITY - The present disclosure provides radiolabeled compounds of the formula: (I) and (II), as well as precursor compounds of the formula: (VII) wherein the variables are defined herein. The present disclosure also provides radiopharmaceutical compositions comprising the radiolabeled compounds disclosed herein as well as precursor compositions comprising the precursor compounds disclosed herein. The present disclosure further provides methods of imaging using the radiolabeled compounds and/or radiopharmaceutical compositions of the present disclosure as well as kits for the preparation of the radiolabeled compounds and radiopharmaceutical compositions disclosed herein. | 07-14-2022 |
| 20220214367 | CALIBRATION METHODS AND COMPOSITIONS FOR BIOMOLECULE ANALYSIS - Calibration standards with known amounts of combinatorial biomolecules, such as GLs, are provided. In some aspects, calibration markers of the embodiments can be used to assess or quantitate the levels of a plurality of biomolecules in a test sample, such as by mass spectrometry. | 07-07-2022 |
| 20220213165 | THERAPEUTIC PEPTIDES - Provided herein are therapeutic peptides. In some aspects, therapeutic peptides are provided that can alter EphB4/EFNB2 signaling and can be used to treat a cancer. In some embodiments, the peptides are comprised in nanoparticles, such as core-cross-linked polymeric micelles (CCPM). | 07-07-2022 |
| 20220211436 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING - Exemplary embodiments of the present disclosure apparatus and methods that provide for subtractive material processing, including efficient and precise ablation of tissues. Certain embodiments include a first laser configured to direct a first pulse of energy at a first wavelength to a region of tissue; a second laser configured to direct a second pulse of energy at a second wavelength to the region of tissue; and a control system configured to control operation of the first laser and the second laser. | 07-07-2022 |
| 20220205035 | METHODS AND APPLICATIONS FOR CELL BARCODING - The current methods and compositions of the disclosure provide a platform for detecting the transcriptomic, genomic, or proteomic profile in relation to particular characteristics of a single cell, such as the location of a cell within a tissus. Accordingly, aspects of the disclosure relate to a method for barcoding eukaryotic cell nuclei comprising: transferring oligonucleotides into the nuclei of cells and performing single-cell analysis to identify the sequence of the barcode; wherein the oligonucleotides comprise a barcode region and a target region. | 06-30-2022 |
| 20220202821 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF - The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein. | 06-30-2022 |
| 20220202747 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SHIGA TOXICOSIS - Methods for treating Shiga toxicosis, caused by infection with Shiga toxin bacteria, are provided. The methods include administering to a subject in need thereof an effective amount of one or more active agents selected from tamoxifen, 4-hydroxytamoxifen, endoxifen, toremifene, raloxifene, bazedoxifene, and pharmaceutically acceptable salts thereof. In some embodiments, the methods further include the administration of an antibiotic or a manganese compound to the subject. Pharmaceutical compositions for the treatment of Shiga toxicosis are also described. | 06-30-2022 |
| 20220098148 | ANTIBIOTIC AMMONIUM COMPOUNDS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS - The present disclosure provides ammonium compounds, e.g., compounds according to Formula I as set forth herein, which are useful as antimicrobial agents. Methods for the treatment of bacterial infections and associated conditions, e.g., gastrointestinal conditions, are also described, as well as methods for altering the microbiome of subjects such as humans. | 03-31-2022 |
| 20220096594 | MACROCYCLIC PEPTIDES FOR TARGETED INHIBITION OF AUTOPHAGY - Provided herein are cyclic peptide inhibitors of autophagy that bind to LC3. These cyclic peptides may be used to treat diseases or disorders associated with autophagy, such as, for example, cancer, diabetes, cardiovascular disease, and neurological disorders. These cyclic peptides may also be used to sensitize cancers to front-line chemotherapy, immunotherapy, and/or radiation therapy. | 03-31-2022 |
| 20220096556 | PRODUCTION OF MEGAKARYOCYTES OR PLATELETS FROM MONOCYTES - We disclose a method, comprising extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow; isolating CD14 | 03-31-2022 |
| 20220096368 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE - Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided. | 03-31-2022 |
| 20220014398 | LOW RESOLUTION OFDM RECEIVERS VIA DEEP LEARNING - Various embodiments provide for deep learning-based architectures and design methodologies for an orthogonal frequency division multiplexing (OFDM) receiver under the constraint of one-bit complex quantization. Single bit quantization greatly reduces complexity and power consumption in the receivers, but makes accurate channel estimation and data detection difficult. This is particularly true for OFDM waveforms, which have high peak-to average (signal power) ratio in the time domain and fragile subcarrier orthogonality in the frequency domain. The severe distortion for one-bit quantization typically results in an error floor even at moderately low signal-to-noise-ratio (SNR) such as 5 dB. For channel estimation (using pilots), various embodiments use novel generative supervised deep neural networks (DNNs) that can be trained with a reasonable number of pilots. After channel estimation, a neural network-based receiver specifically, an autoencoder jointly learns a precoder and decoder for data symbol detection. | 01-13-2022 |
| 20220010023 | BAFF-R TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELLS AND USES THEREOF - Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided. | 01-13-2022 |
| 20220003221 | POLYMER FIBER ACTUATORS - Actuators (artificial muscles) comprising twist-spun nanofiber yarn or twist-inserted polymer fibers generate actuation when powered electrically, photonically, chemically, thermally, by absorption, or by other means. These artificial muscles utilize polymer fibers non-coiled or coiled yarns and can be either neat or comprising a guest. Devices comprising these artificial muscles are also described. In some embodiments, thermally-powered polymer fiber torsional actuator has a twisted, chain-oriented polymer fiber that has a first degree of twist at a first temperature and a second degree of twist at a second temperature in which the bias angles of the first degree and second degree of twist are substantially different. | 01-06-2022 |
| 20220002723 | METHODS FOR THE TREATMENT OF SMALL ROUND CELL TUMORS - Provided herein are methods for treating small round cell tumor(s) by administering anti-androgen receptor therapy to a subject. The anti-androgen receptor therapy may comprise an AR antisense oligonucleotide and may be administered in combination with an additional anti-cancer agent. | 01-06-2022 |
| 20210405041 | PARTICLE-BASED SENSORS AND METHODS USING PARTICLE-BASED SENSORS FOR DETECTION OF ANALYTES - The disclosure relates to particle-based assays for the detection of analytes. Using various combinations of particular technologies, including gold nanorods, silver nanoparticles, gold/silver nanoshells, gold/silver nanocages and nanobubble detection, enhanced detection limits can be achieved across a large range of analytes. | 12-30-2021 |
| 20210395359 | Weight Loss Regimen - Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof. | 12-23-2021 |
| 20210394391 | Additive Manufacturing of Polymer Ceramics - Scalable 3D-printing of ceramics includes dispensing a preceramic polymer at the tip of a moving nozzle into a gel that can reversibly switch between fluid and solid states, and subsequently thermally cross-linking the entire printed part “at-once” while still inside the same gel. The solid gel, including mineral oil and silica nanoparticles, converts to fluid at the tip of the moving nozzle, allows the polymer solution to be dispensed, and quickly returns to a solid state to maintain the geometry of the printed polymer both during printing and the subsequent high temperature (160° C.) cross-linking. The cross-linked part is retrieved from the gel and converted to ceramic by high temperature pyrolysis. This scalable process opens new opportunities for low-cost, high-speed production of complex 3-dimensional ceramic parts, and will be widely used for high temperature and corrosive environment applications, including electronics and sensors, microelectromechanical systems, energy, and structural applications. | 12-23-2021 |
| 20210393753 | FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF - Provided herein is an FGL2 neutralization cell therapy comprising immune cells expressing a FGL2 neutralization construct. Further provided are methods for the treatment of cancer comprising administering the FGL2 neutralization cell therapy. | 12-23-2021 |
| 20210386838 | HUMAN-ENZYME MEDIATED DEPLETION OF HOMOCYSTEINE FOR TREATING PATIENTS WITH HYPERHOMOCYSTEINEMIA AND HOMOCYSTINURIA - Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-γ-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids. | 12-16-2021 |
| 20210380962 | ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES FOR THERAPEUTIC USES - Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-γ-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes. | 12-09-2021 |
| 20210369531 | KIT, TOOLS, AND METHOD FOR TREATMENT OF FACIAL INJURIES AND DISORDERS - The present invention includes an intraoral tool, including one or more selected solid or inflatable inserts targeted to provide a low load prolonged stretch to orofacial musculature that may be coupled to tool handle or tool mounting bracket, wherein the intraoral tool is configured for a delivery of intraoral treatment, such as a stretch to a patient's facial injury or disorder and configured to permit manipulation of the insert in the patient's mouth. | 12-02-2021 |
| 20210363215 | T CELL RECEPTORS WITH MAGE-B2 SPECIFICITY AND USES THEREOF - The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells. | 11-25-2021 |
| 20210361655 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 19 MUTATIONS - The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib. | 11-25-2021 |
| 20210355443 | METHODS FOR PRODUCTION OF TISSUE RESIDENT MEMORY-LIKE T CELLS AND USE THEREOF - Provided herein are methods for the production of tissue resident memory-like T cells by the combination of hypoxia and TGFβ. Further provided herein are methods of using the tissue resident memory T cells as adoptive cell therapy. | 11-18-2021 |
| 20210340232 | MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND USES THEREOF - Provided herein are methods and reagents for increasing chemosensitivity to chemotherapy and immunotherapy in cancer patients. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an DKK3-neutralizing agent, such as a DKK3-neutralizing antibody provided herein. The methods can further include administering an effective amount of chemotherapy or immunotherapy to said patient. | 11-04-2021 |
| 20210330741 | POLYPEPTIDE THERAPEUTICS AND USES THEREOF - Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI). | 10-28-2021 |
| 20210320574 | HIGH TORQUE DENSITY DOUBLE STATOR PERMANENT MAGNET ELECTRIC MACHINE - A novel high torque density double stator permanent magnet electric machine is provided. An outer stator is provided which has complex teeth and optionally can have windings every tooth or every other tooth. A rotor is provided having a plurality of magnet receivers, each with a complex topology. Magnets are provided in the rotor which are tangentially magnetized with alternating polarities and a complex topology to increase torque density. An inner stator is provided having a plurality of teeth with complex topologies. Windings are provided around every tooth or every other tooth, alternatively. Air-gaps are provided between the outer stator and the rotor and between the rotor and inner stator. The air-gap between the inner stator and the rotor is smaller than the air-gap between the outer stator and the rotor. A lower current density in certain windings improves thermal response without comprising average torque. | 10-14-2021 |
| 20210312183 | SYSTEM AND METHOD FOR HUMAN ACTION RECOGNITION AND INTENSITY INDEXING FROM VIDEO STREAM USING FUZZY ATTENTION MACHINE LEARNING - A system and method are provided for accurately recognizing actions and estimating action intensity. To enable the system to deal with the uncertainty and varied nature inherent in action recognition and intensity indexing, the system is a hybrid system that combines the concept of fuzzy logic and deep recurrent neural networks. The methodology is an attentive neuro-fuzzy system designed to recognize qualitative differences in human actions and to self-adapt to different intensities. The model of the system and method utilizes recurrent neural networks to detect actions from spatio-temporal patterns of human poses, in tandem with an adaptive fuzzy inference system to learn the various human motions used to perform actions with different intensities and then estimate the action's intensity. The integrated model can successfully learn the unique way a specific action with a certain intensity is performed and can estimate the intensity of the respective action. | 10-07-2021 |
| 20210308287 | METHOD FOR EXTRACTION AND PURIFICATION OF 68GA - Disclosed herein are methods preparing a purified, carrier-free 68Ga solution. Tire present disclosure also provides systems for preparing a purified, carrier-free 68Ga solution. The present disclosure also provides compositions comprising the purified, carrier-free 68Ga solutions disclosed herein. Also provided are methods of administering compositions of the present disclosure to a patient in need thereof, for example, for imaging a disease or disorder, such as cancer. | 10-07-2021 |
| 20210198817 | ACTUATING TEXTILES CONTAINING POLYMER FIBER MUSCLES - A smart (intelligent) textile that can control its porosity, shape, texture, loft, stiffness, or color by temperature change or moisture absorption by using polymer fiber torsional and tensile actuators. This temperature change can be due to a change in ambient temperature or by an external stimulus, such as electrothermal heating. Mechanisms to accomplish this include (a) direct actuation (contraction or expansion) of polymer fiber actuators in a textile structure (b) rotation of polymer fiber actuators helically wrapped around warp and/or weft yarns in a textile structure; (c) rotation of chenille type or ribbon-like warp (or weft) ends by polymer fiber torsional actuators; (d) contraction or expansion of piles or loops in a chenille type fancy yarn produced by using mandrel actuators as pile or loop part of the yarn; (e) buckling of warp (or weft) yarns by contraction of tensile polymer fiber actuators; (f) decrease in yarn diameter by a twisting effect of polymer fiber actuators; (g) contraction or expansion of segmented mandrel actuators with core filament, wire or yarns; or (h) rotation of differentially dyed polymer fiber actuators for color changing textiles. | 07-01-2021 |
| 20210198370 | BI-SPECIFIC ANTIBODIES AND USE THEREOF - The present disclosure provides a bispecific antibody comprising an IgG linked to an scFv, wherein the VH domain of the IgG is linked to the VH domain of the scFv, the bispecific antibody binding a human vascular endothelial growth factor (VEGF) family protein and an epidermal growth factor receptor (EGFR) family protein. Further embodiments provide pharmaceutical compositions comprising the bispecific antibody of the embodiments and aspects thereof and a pharmaceutically acceptable carrier. Further embodiments provide various methods of treating cancer in a subject comprising administering a bispecific antibody of the embodiments and aspects thereof to the subject. A further embodiment provides a kit comprising the bispecific antibody. | 07-01-2021 |
| 20210198360 | HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFOR - The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1. | 07-01-2021 |
| 20210196753 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CELLS BY INDUCTION OF CYTOTOXIC OXIDATIVE STRESS - Provided herein are methods and compositions for the treatment of cancers with D-VC and arsenic trioxide. In some aspects, cancers for treatment according to the embodiments include cancers with increased GLUT1 expression and/or comprise KRAS mutation. | 07-01-2021 |
| 20210196713 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES - The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin. | 07-01-2021 |
| 20210180133 | METHOD TO IDENTIFY SUBJECTS AT HIGHER RISK TO DEVELOP AN AUTOIMMUNE DISEASE BASED ON GENETIC AND/OR PHENOTYPIC SCREENING FOR EPISTATIC VARIANTS IN DDX39B (RS2523506) AND IL7R (RS6897932) - The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R. | 06-17-2021 |
| 20210178023 | ANTIMICROBIAL WRAPS FOR MEDICAL IMPLANTS - Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided. | 06-17-2021 |
| 20200412366 | Reversible Computing System and Method Based on Conservative Magnetic Skyrmion Logic - A skyrmion logic gate is provided. The logic gate comprises a first track configured for propagation of magnetic skyrmions and a second track configured for propagation of magnetic skyrmions. A junction links the first and second tracks. A continuous current flows through the logic gate, wherein skyrmions propagate due to the current. | 12-31-2020 |
| 20200410855 | COLLABORATIVE DISTRIBUTED AGENT-BASED TRAFFIC LIGHT SYSTEM AND METHOD OF USE - In this disclosure, collaborative multi-agent-based TST is presented with dedicated intersection controllers that include software agents which read local and remote detection systems and then collaboratively optimize signal timing phases by considering the feedback of all controller agents that may be affected by a change. The disclosure also presents an augmented system which considers network input from handheld remote devices to update certain traffic light phase information and adapt to emerging emergency situations. | 12-31-2020 |
| 20200113939 | REGULATORY B CELLS AND USES THEREOF - Provided herein are methods for producing stimulated populations of regulatory B cells comprising treating an isolated population of B cells with stimulatory agents, such as CpG oligonucleotides, BCR ligation, and CD40 ligand. Also provided herein are methods of treating immune disorders, such as chronic graft versus host disease, with the stimulated population of regulatory B cells. | 04-16-2020 |
| 20200088175 | THERMALLY-POWERED COILED POLYMER FIBER TENSILE ACTUATOR SYSTEM AND METHOD - Actuators (artificial muscles) comprising twist-spun nanofiber twist-inserted polymer fibers generate tensile actuation when powered electrically, photonically, chemically, thermally, by absorption, or by other means. These artificial muscles utilize coiled polymer fibers and can be either neat or comprising a guest. In some embodiments, the coiled polymer fibers actuator can be incorporated into an article, such as a textile, braid, clothing, smart packaging, or a mechanical system, and the coiled polymer fiber in the coiled polymer fiber actuator can have a stroke amplification factor of 5 or greater. | 03-19-2020 |
| 20200087150 | Facile Direct Functionalization of Pristine Graphene Nanoparticles - Graphene is a single layer carbon-based material known for high strength, high flexibility, high electrical conductivity, high surface area, hydrophobicity and barrier property. Introduction of surface functional groups on graphene enhances most of these properties. A facile and economical process to prepare amine and fluoride functionalized graphenes is disclosed. The disclosed processes utilize direct functionalization of pristine graphene without pre-functionalization (GO). Successful functionalization of both aminated and fluorinated graphenes were confirmed by the analyses of FT-IR, thermal gravimetric analysis (TGA), Raman, UV-Vis, and dispersion study. Amine functional groups can react with epoxy resin and urethane resin to form a covalent bond, and fluorinated graphene can give high hydrophobicity and durability, therefore both can be applied as a material or a component in polymer and composite coatings for corrosion protection, moisture or gas barriers. | 03-19-2020 |
| 20190317378 | Magnetoelectric-Based Systems And Methods For Modulating Terahertz Beams | 10-17-2019 |
| 20190316110 | RECOMBINANT POLYPEPTIDES COMPRISING SELENOCYSTEINE AND METHOD FOR PRODUCING THE SAME | 10-17-2019 |
| 20190002283 | FABRICATION AND APPLICATION OF NANOFIBER RIBBONS AND SHEETS AND TWISTED AND NON-TWISTED NANOFIBER YARNS - A nanofiber forest on a substrate can be patterned to produce a patterned assembly of nanofibers that can be drawn to form nanofiber sheets, ribbons, or yarns. | 01-03-2019 |
| 20180375478 | CMOS RF Front-End of Transmitter for Rotational Spectroscopy - A radio frequency (RF) front-end for a transmitter in a complementary metal-oxide-semiconductor (CMOS) includes a mixer based core that itself includes first and second input signals; an amplifier that amplifies the first signal and transmits a corresponding amplified first signal; an up-conversion mixer that receives the amplified first signal and the second signal through transistors, and mixes the amplified first signal and second signal and generates a radio frequency (RF) signal; and an antenna that receives the RF signal and transmits the signal from the front-end. | 12-27-2018 |
| 20180371106 | MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE - The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided. | 12-27-2018 |
| 20180369277 | Compositions Comprising Citrate and Applications Thereof - In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression. | 12-27-2018 |
| 20180368918 | UTILIZATION OF LASER INTERSTITIAL THERMOTHERAPY GUIDED WITH REAL TIME THERMAL MRI - Methods, apparatus, and kits for applying thermal energy to tissue in a region of interest. Certain embodiments include registration of fiducial markers with an image guidance system and temperature monitoring via magnetic resonance imaging thermography. | 12-27-2018 |
| 20180159190 | SOLAR ENERGY SYSTEMS - In one aspect, solar energy systems are described herein. In some embodiments, such a comprises an electrochemical cell comprising a photoelectrode, a counter electrode, and an ion transport membrane disposed between the photoelectrode and counter electrode. The cell further comprises a first electrolyte solution disposed in fluid communication with the photoelectrode and the membrane, and a second electrolyte solution disposed in fluid communication with the membrane and the counter electrode. The first and/or second electrolyte solution comprises a solvated redox pair. Additionally, the cell also comprises a storage electrode, a first external electrical connection between the photoelectrode and the counter electrode, and a second external electrical connection between the counter electrode and the storage electrode. Components of the system define a liquid junction photovoltaic cell under light conditions and a galvanic cell under dark conditions. | 06-07-2018 |
| 20180108430 | METHOD AND SYSTEM FOR POPULATION HEALTH MANAGEMENT IN A CAPTIVATED HEALTHCARE SYSTEM - Methods and systems are provided for managing patient or patient populations within a fully integrated captivated healthcare system, which includes creating a patient profile or a patient population profile; screening, assessing and treating a patient or patient population; reviewing, analyzing, and comparing a patient or patient population to a control group or pre-treatment patient profile or patient population profile; and prioritizing, scheduling, and care coordination for a patient or patient population as part of follow-up healthcare assessment and services included in the fully integrated healthcare delivery system. Part of the methods and system includes the ability to utilize comparative patient and patient population data to assess and control healthcare access, quality, and costs. | 04-19-2018 |
| 20170175125 | Inhibition of Bruton's Tyrosine Kinase (Btk) in the Lung to Treat Severe Lung Inflammation and Lung Injury - Bruton's tyrosine kinase (Btk) plays an important role in the pathophysiology of local inflammation in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). A unique two hit model of ALI induced by lipopolysaccharide (LPS)/immune complex (IC)—was developed, along with viral-induced ALI caused by influenza virus and COPD caused by second hand smoke. Two types or therapeutics (i) Anti-neutrophil antibodies, and specifically their F(ab′) | 06-22-2017 |
| 20170166455 | SOLAR POWERED THERMAL DISTILLATION WITH ZERO LIQUID DISCHARGE - A solar powered thermal distillation system and method includes a solar still having a first end and an opposite second end with a longitudinal access extending between the first end and the opposite second end, the solar still further having a raised side and an opposite lowered side with a width axis extending between the raised side and the opposite lowered side. A solar-transmitting roof is located atop the solar still, wherein the solar-transmitting roof admits solar energy to equipment maintained within the solar still. The solar sill also includes a heating surface inclined along a direction aligned with or parallel to the width axis so that water flows down the heating surface along or parallel with the width axis, and a tubular member extending below the heating surface between the raised side and the opposite lowered side. | 06-15-2017 |
| 20170152260 | STAT3 INHIBITOR - Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer. | 06-01-2017 |
| 20170139326 | Ordering Block Copolymers - A method for ordering block copolymers including forming a first layer having a first preference mode; and providing a reactive agent in selected regions of the first layer that modifies the selected regions to a second preference mode, wherein the selected regions define other regions of the first layer retaining the first preference mode thereby forming an alignment layer for block copolymers. | 05-18-2017 |
| 20170137290 | FABRICATION AND APPLICATION OF NANOFIBER RIBBONS AND SHEETS AND TWISTED AND NON-TWISTED NANOFIBER YARNS - Fabricating a nanofiber sheet, ribbon, or yarn by a continuous process that includes synthesizing a nanofiber forest in a furnace growth region on a substrate, wherein the nanofiber forest comprises a parallel array of nanofibers, and further includes drawing said nanofibers from the nanofiber forest to form a primary assembly that is the sheet, ribbon or yarn. The substrate continuously moves from the furnace growth region into a region where the nanofibers in the forest are drawn. | 05-18-2017 |
| 20170044514 | ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES | 02-16-2017 |
| 20170044423 | GEMINI EPOXIDE SURFACTANT COMPOSITIONS | 02-16-2017 |
| 20170020825 | NOVEL FORMULATIONS OF VOLATILE ANESTHETICS AND METHODS OF USE FOR REDUCING INFLAMMATION - The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site. | 01-26-2017 |
| 20160381054 | SYSTEM AND DEVICE FOR PREVENTING ATTACKS IN REAL-TIME NETWORKED ENVIRONMENTS - Disclosed are various embodiments of a system or method for the transparent handling of real-time streaming application-level data. The disclosed embodiments permit the identification and modification of specified file patterns from within the live stateful data transactions across computer networks. The system includes a unidirectional in-line communications data stream handler, stream pattern detector, stream file modification processor, and memory management subsystem. Embodiments of the disclosure may include devices permitting incoming network data streams to be captured, processed, and selectively modified when implemented on a digital streaming network communications line. One embodiment of the system includes techniques for mitigation of malicious software directed against software based network connected systems. Other embodiments may make use of approaches for digital data hiding and covert channel obfuscation operations on digital multimedia files being transferred through the system. In a non-limiting example, session-unique digital tags may be embedded within real-time data flows of multimedia files, the product of which may be used to enforce privacy policies, intellectual property management, copyright protection, as well as digital content delivery management. | 12-29-2016 |
| 20160374978 | ANTIMICROBIAL COMPOSITIONS COMPRISING GLYCERYL NITRATES - Provided are antimicrobial solutions comprising a glyceryl nitrate (e.g., glyeryl trinitrate) in combination with a chelator (e.g., citrate), a peroxide, a fatty acid, and/or an alcohol (e.g., ethanol). In various aspects these components may synergistically act to kill or reduce the growth of microbes, such as bacteria or fungi, present in a biofilm. | 12-29-2016 |
| 20160187447 | METHOD AND APPARATUS FOR SEPARATING CHEMICAL SPECIES IN MAGNETIC RESONANCE IMAGING - A method that includes obtaining an MRI gradient echo train of at least three echo data sets at differing phase angles; producing a plurality of phase error maps among the at least three echo data sets; and imaging at least three distinct chemical species based on the plurality of phase error maps. | 06-30-2016 |
| 20160185745 | ANALOGS OF VINAXANTHONE AND XANTHOFULVIN, METHODS OF SYNTHESIS, AND METHODS OF TREATMENTS THEREOF - The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof. | 06-30-2016 |
| 20160184621 | Drug Disposal System - A safe and effective system for removal of a range of common pharmaceutical compounds. The formulation comprises activated carbon, accompanied by a dissolution aid, such as a larger pebble-like material, in the presence of an acidified liquid medium. In one exemplary method, drugs are added to the formulation in a container, whereby chemicals contained within the drug are irreversibly adsorbed onto activated carbon, thereby rendering them inactive and sequestered from further use. | 06-30-2016 |
| 20160184336 | ESTERS OF 2-DEOXY-MONOSACHARIDES WITH ANTI PROLIFERATIVE ACTIVITY - Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed. | 06-30-2016 |
| 20160160073 | Methods and Compositions for Material Extrusion 3D Printing - Methods and compositions directed to blends of acrylonitrile butadiene styrene (ABS) with styrene ethylene butadiene styrene (SEBS) are disclosed. In certain aspects, the blends further include an ultrahigh molecular weight polyethylene (UHMWPE). In a further aspect, the blends are compatible with 3D printing platforms. | 06-09-2016 |
| 20160147959 | SYSTEMS, APPARATUSES AND METHODS FOR PREDICTING MEDICAL EVENTS AND CONDITIONS REFLECTED IN GAIT - A system for predicting medical events and conditions that are reflected in gait may include a data capture subsystem configured to capture data pertaining to a position and/or motion of a patient, a data analysis and outcome generation subsystem configured to analyze the captured data and to generate output pertaining to a likelihood of the patient experiencing a medical event or medical condition, and a user interface subsystem configured to provide the output to a user, e.g., healthcare provider, and to receive feedback from the user. Methods for predicting medical events and conditions reflected in gait are also provided. | 05-26-2016 |
| 20160145279 | STAT6 INHIBITORS - The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer. | 05-26-2016 |
| 20160145250 | ANTI-CANCER COMPOUNDS - Provided are methods and compositions for the treatment of diseases such as cancer. In certain aspects, compounds which can inhibit Skp2 are provided. Specifically chromenone derivatives are disclosed that have the capability toward reducing differentiation of pluripotent, multipotent or totipotent cells and thus have therapeutic utility in the treatment of a proliferative disease such as cancer. | 05-26-2016 |
| 20160138596 | AXIAL-FLOW PUMPS AND RELATED METHODS - Miniature (mesoscale) axial-flow pumps including an inlet guide, a stator spaced apart from the inlet guide, and a rotor rotatably disposed between the inlet guide and the stator. | 05-19-2016 |
| 20160138133 | Extraction and Recovery of Yttrium and Rare Earth Elements - Methods for extraction and recovery of rare earth elements are disclosed. In one aspect, heap leaching with a leach solution comprising sulfuric acid is used to extract rare earth elements including yttrium and light and heavy rare earth elements. | 05-19-2016 |
| 20160137776 | Fluorescent Polymers and Applications Thereof - In one aspect, block copolymers are described herein. A block copolymer described herein, in some embodiments, comprises a first block comprising a polymer or oligomer formed from the reaction product of (i) a polycarboxylic acid or a polycarboxylic acid equivalent, (ii) a polyol, and (iii) an amino acid; and a second block comprising a polymer or oligomer that differs from the polymer or oligomer of the first block. In some cases, the polycarboxylic acid or polycarboxylic acid equivalent comprises citric acid, a citrate, or an ester of citric acid. The polyol can comprise an α,ω-n-alkane diol, poly(ethylene glycol), or poly(propylene glycol). In some embodiments, the amino acid forms a pendant group of the polymer or oligomer of the first block and/or forms a luminescent 6-membered ring with the polycarboxylic acid or polycarboxylic acid equivalent. The second block of a block copolymer described herein, in some embodiments, comprises a polylactone. | 05-19-2016 |
| 20160122825 | EFFICIENT FUNCTIONAL GENOMICS PLATFORM - Methods for identifying oncogenic biomarkers specific to a patient's cancer. Methods are also provided for identifying candidate therapeutic agents for treating a patient's cancer based on the oncogenic biomarkers. Methods for treating patient's having cancers that express mutant PIK3R1 and ras genes are also disclosed. | 05-05-2016 |
| 20160122649 | MODIFICATION OF RHEOLOGICAL PROPERTIES OF THERMOTROPIC LIQUID CRYSTALLINE POLYMERS FOR MANUFACTURING FILM PRODUCTS - In some embodiments, a compound and/or method of making a compound includes the modification of rheological properties of thermotropic main chain liquid crystalline polymers (LCPs) by melt state reactive processing. The modified liquid crystalline polymer may have an increased viscosity while retaining its liquid crystal properties. | 05-05-2016 |
| 20160117599 | User-Powered Recommendation System - Recommendation systems are widely used in Internet applications. In current recommendation systems, users only play a passive role and have limited control over the recommendation generation process. As a result, there is often considerable mismatch between the recommendations made by these systems and the actual user interests, which are fine-grained and constantly evolving. With a user-powered distributed recommendation architecture, individual users can flexibly define fine-grained communities of interest in a declarative fashion and obtain recommendations accurately tailored to their interests by aggregating opinions of users in such communities. By combining a progressive sampling technique with data perturbation methods, the recommendation system is both scalable and privacy-preserving. | 04-28-2016 |
| 20160113906 | METHODS OF PREPARING EXTRUDATES - Compositions and methods of preparing amorphous drug formulations through hot melt extrusion which result in decreased decomposition of the desired drug are provided herein. Also provided are methods and compositions which further comprise a pharmaceutically acceptable thermoplastic polymer. In some embodiments, these compositions comprise a therapeutically active agent which is only sparingly soluble in water. | 04-28-2016 |
| 20160111707 | FABRICATION OF BISCROLLED FIBER USING CARBON NANOTUBE SHEET - Fabrication of yarns or other shaped articles from materials in powder form (or nanoparticles or nanofibers) using carbon nanotube/nanofiber sheet as a platform (template). This includes methods for fabricating biscrolled yarns using carbon nanotube/nanofiber sheets and biscrolled fibers fabricated thereby. | 04-21-2016 |
| 20160103227 | LARGE-VOLUME SCINTILLATOR DETECTOR FOR RAPID REAL-TIME 3-D DOSE IMAGING OF ADVANCED RADIATION THERAPY MODALITIES - An apparatus and method for measuring three-dimensional radiation dose distributions with high spatial and temporal resolution using a large-volume scintillator. The scintillator converts the radiation dose distribution into a visible light distribution. The visible light is transported to one or more photo-detectors, which measure the light intensity. The light signals are processed to correct for optical artifacts, and the three-dimensional light distribution is reconstructed. The reconstructed light distribution is post-processed to convert light amplitudes to measured radiation doses. The high temporal resolution of the detector makes it possible to observe the evolution of a dynamic dose distribution as it changes over time. Integral dose distributions can be measured by summing the dose over time. | 04-14-2016 |
| 20160101308 | Drug Disposal System - The present invention comprises a safe and effective system for removal of a range of common pharmaceutical compounds. The formulation comprises activated carbon, accompanied by some larger pebble-like material to help break up capsules and tablets upon shaking, in the presence of an acidified liquid medium. Drugs are added to the bottle and the bottle is shaken so that the drugs are dissolved by the liquid solution and are irreversibly adsorbed onto activated carbon, thereby sequestering them from further use. | 04-14-2016 |
| 20160096902 | CHIMERIC ANTIGEN RECEPTOR-TARGETING MONOCLONAL ANTIBODIES - Provided are monoclonal antibodies that detect CD 19 CAR-modified immune cells and CAR-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of CAR-modified immune cells. | 04-07-2016 |
| 20160087342 | CIRCUIT-LOADED CONFORMAL METASURFACE CLOAK - An electromagnetic invisibility cloaking device with a broadened cloaking bandwidth and/or a tunable frequency of operation. The cloaking device includes an object (e.g., antenna) and a metasurface ( | 03-24-2016 |
| 20160083872 | FABRICATION OF NANOFIBER RIBBONS AND SHEETS - Fabricating a nanofiber ribbon or sheet with a process that includes providing a primary assembly by arranging carbon nanotube nanofibers in aligned arrays, the arrays having a degree of inter-fiber connectivity, drawing the carbon nanotube nanofibers from the primary assembly into a sheet or ribbon, and depositing the sheet or ribbon on a substrate. | 03-24-2016 |
| 20160074560 | ANTIMICROBIAL CATHETERS - Antimicrobial catheters and medical devices are provided. In some aspects, a low durometer aliphatic polyether polyurethane may be impregnated with a first antimicrobial agent (e.g., minocycline and rifampin) and coated with a second antimicrobial agent (e.g., chlorhexidine, gendine, or gardine). The antimicrobial catheters may display improved flexibility and resistance to kinking. Methods of producing the antimicrobial catheters are also provided. | 03-17-2016 |
| 20160074559 | ANTIMICROBIAL WRAPS FOR MEDICAL IMPLANTS - Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided. | 03-17-2016 |
| 20160069902 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 03-10-2016 |
| 20160068604 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 03-10-2016 |
| 20160060260 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE - Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: | 03-03-2016 |
| 20160058759 | GLUTAMINASE INHIBITOR THERAPY - Disclosed herein are methods of treating a subject having an altered NRF2/KEAP1 pathway, and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject. | 03-03-2016 |
| 20160040514 | Reservoir Characterization and Hydraulic Fracture Evaluation - A multi-physics and multi-scale system and process to simulate imaging of hydrocarbon reservoirs using electromagnetic particles and electromagnetic tomography. Embodiments are applicable towards flood-front mapping and hydraulic fracture imaging. With respect to flood-front mapping, coated nanoparticles (or their software representation) may be injected. In case of fracture imaging, the contrast agents (or their software representation) may either be injected as proppants, fibers, or nanoparticles suspended in the solution. | 02-11-2016 |
| 20160038311 | LAYERING TECHNIQUE FOR AN ADJUSTABLE, REPAIRABLE VARIABLE STIFFNESS PROSTHETIC FOOT - A modular prosthetic foot includes a keel section and in some cases, an optional heel section. The keel section may also include an optional toe section. The keel section can include separate layers of various stiffnesses, wherein the optional toe section and the optional heel section are composed of varying stiffness layers nested together. The stiffness of the keel section is adjustable by a user without specialized tools. The components of the prosthetic foot are modular and can be removed and exchanged without altering the fit and alignment of the prosthetic foot. | 02-11-2016 |
| 20160036132 | ANISOTROPIC METAMATERIALS FOR ELECTROMAGNETIC COMPATIBILITY - Embodiments of the invention are directed to a device having one or more electromagnetic components embedded in an anisotropic metamaterial (AM) comprising an array of asymmetric unit cells comprising a substrate forming a plurality of channels or spaces having at least one material with different electromagnetic properties included in the channels or spaces in the first material forming an anisotropic metamaterial. | 02-04-2016 |
| 20160034441 | SYSTEMS, APPARATUSES AND METHODS FOR GENERATING A USER INTERFACE - Systems, apparatuses and methods for generating a graphical user interface (GUI) conforming to a graphical representation employ computer vision, optical character recognition, and other techniques to generate a structure of the GUI as a view hierarchy. A development project with source code and resource files is created to generate an application having the GUI. The application and GUI are applicable to mobile and other platforms using various operating systems, such as Android, iOS, and others. | 02-04-2016 |
| 20160025728 | BRAIN-SPECIFIC GENE SIGNATURE OF TUMOR CELLS - The present disclosure provides a method of detecting and diagnosing metastatic spread of cancer to the brain by analyzing the product of a gene signature. Gene signatures detailed herein are specific to the brain metastasis and not dependent upon the genetic signature of the primary tumor. Accordingly, disclosed method can be used to guide therapeutic intervention and further diagnostic analysis. | 01-28-2016 |
| 20160024503 | miRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND THERAPY - Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes. | 01-28-2016 |
| 20160022728 | miRNA FOR TREATING CANCER AND FOR USE WITH ADOPTIVE IMMUNOTHERAPIES - In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy. | 01-28-2016 |
| 20160002523 | DETERMINATION OF OIL SATURATION IN RESERVOIR ROCK USING PARAMAGNETIC NANOPARTICLES AND MAGNETIC FIELD - Methods for detection of the presence and distribution of oil in subsurface formation are described herein. The present invention involves injection of an aqueous dispersion of the nanoparticles into the potentially oil containing subsurface formation, followed by a remote detection of the oscillation responses of the nanoparticles in the oil/water interfaces in the reservoir rock by applying magnetic field. | 01-07-2016 |
| 20160002248 | GLS1 INHIBITORS FOR TREATING DISEASE - Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: | 01-07-2016 |
| 20160002204 | GLS1 INHIBITORS FOR TREATING DISEASE - Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: | 01-07-2016 |
| 20150374887 | DEVICES AND METHODS FOR THE PREVENTION AND TREATMENT OF NEUROMAS - In one aspect, nerve growth inhibition devices are described herein. In some embodiments, a nerve growth inhibition device described herein comprises a tube having a proximal end and a distal end. A matrix material is disposed in the tube, and the matrix material comprises one or more microchannels. The proximal end of the tube comprises an opening operable to receive nerve tissue, the distal end of the tube is sealed, and the microchannels of the matrix material extend from the proximal end of the tube toward the distal end of the tube. | 12-31-2015 |
| 20150361031 | STAT3 INHIBITOR - Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer. | 12-17-2015 |
| 20150359945 | ANTIMICROBIAL COATINGS - Provided are polymer-based surfaces (e.g., gloves) with an antimicrobial coating, e.g., comprising chlorhexidine and a partially hydrolyzed polyvinyl acetate copolymer, or a biguanide and a silicone. Methods of coating polymer-based surfaces with antimicrobial compositions are also provided. | 12-17-2015 |
| 20150359840 | Autophagy-Inducing Peptide Analogs - An autophagy-inducing compound comprises an autophagy-inducing peptide comprising Beclin 1 peptides immediately N- and C-terminally flanked by moieties R | 12-17-2015 |
| 20150353936 | ANTIGENE OLIGOMERS INHIBIT TRANSCRIPTION - Transcription of a gene in a mammalian cell is methylase-independently inhibited by contacting the cell with a nucleic acid oligomer of 12-28 bases complementary to a partially single-stranded target genomic sequence of the gene. | 12-10-2015 |
| 20150343056 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY - Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2′3-cGAMP, 2′2-cGAMP, 3′2′-cGAMP and 3′3′-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics. | 12-03-2015 |
| 20150316631 | METHODS AND APPARATUS FOR PHASE CORRECTION IN MAGNETIC RESONANCE IMAGING - Methods, apparatuses, systems, and software for extended phase correction in phase sensitive magnetic resonance imaging utilizing an optimized region-growing based phase correction algorithm. Phase correction is formulated as selecting a vector for each pixel of an image from two input candidate vectors so that the orientation of the output vector is spatially smooth. In certain embodiments, the optimized region growing algorithm uses automated quality guidance for determining the sequence of region growing and jointly considers the two input candidate vectors during region growing. Further, the algorithm tracks the quality and the mode at each step of the processing. Spatially isolated tissue regions are automatically segmented and processed with different threads of region growing and the correct vector is reliably identified as the output vector for each thread of region growing. Final phase correction was performed by pixel level optimization. | 11-05-2015 |
| 20150315726 | FABRICATION OF BISCROLLED FIBER USING CARBON NANOTUBE SHEET - Fabrication of yarns or other shaped articles from materials in powder form (or nanoparticles or nanofibers) using carbon nanotube/nanofiber sheet as a platform (template). This includes methods for fabricating biscrolled yarns using carbon nanotube/nanofiber sheets and biscrolled fibers fabricated thereby. | 11-05-2015 |
| 20150315661 | NON-INVASIVE DETECTION OF BLADDER CANCER BY FLOURESCENCE IN SITU HIBRIDIZATION OF AURORA A - We disclose a method of detecting bladder cancer in a patient, comprising isolating bladder cells from the patient's urine; hybridizing the bladder cells with a labelled DNA probe, wherein the probe recognizes at least a portion of the aurora kinase A gene, to yield a sample of bladder cells hybridized with the labeled DNA probe: and counting the number of bladder cells in the sample, the number of copies of the aurora kinase A gene in each bladder cell in the sample, and the number of bladder cells in the sample having at least a first threshold number of copies of the aurora kinase A gene. | 11-05-2015 |
| 20150315281 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 11-05-2015 |
| 20150308018 | FABRICATION AND APPLICATION OF NANOFIBER RIBBONS AND SHEETS AND TWISTED AND NON-TWISTED NANOFIBER YARNS - The present invention is directed to nanofiber yarns, ribbons, and sheets; to methods of making said yarns, ribbons, and sheets; and to applications of said yarns, ribbons, and sheets. In some embodiments, the nanotube yarns, ribbons, and sheets comprise carbon nanotubes. Particularly, such carbon nanotube yarns of the present invention provide unique properties and property combinations such as extreme toughness, resistance to failure at knots, high electrical and thermal conductivities, high absorption of energy that occurs reversibly, up to 13% strain-to-failure compared with the few percent strain-to-failure of other fibers with similar toughness, very high resistance to creep, retention of strength even when heated in air at 450° C. for one hour, and very high radiation and IJV resistance, even when irradiated in air. Furthermore these nanotube yarns can be spun as one micron diameter yarns and plied at will to make two-fold, four-fold, and higher fold yarns. Additional embodiments provide for the spinning of nanofiber sheets having arbitrarily large widths. In still additional embodiments, the present invention is directed to applications and devices that utilize and/or comprise the nanofiber yarns, ribbons, and sheets of the present invention. | 10-29-2015 |
| 20150306160 | ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES - The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway. | 10-29-2015 |
| 20150297631 | TUSC2 THERAPIES - A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. | 10-22-2015 |
| 20150292112 | METHODS OF FORMING GRAPHENE SINGLE CRYSTAL DOMAINS - A method of forming graphene single crystal domains on a carbon substrate is described. | 10-15-2015 |
| 20150292030 | METHODS OF CHARACTERIZING AND TREATING MOLECULAR SUBSET OF MUSCLE-INVASIVE BLADDER CANCER - The present application discloses a method of diagnostic testing of primary tumors, circulating tumor cells, serum, and urine to detect high-risk bladder cancers. These results have immediate implications for prognostication and the clinical management of muscle-invasive bladder cancer. | 10-15-2015 |
| 20150284716 | METHOD FOR SINGLE CELL SEQUENCING OF MIRNAS AND OTHER CELLULAR RNAS - Provided herein are methods for single cell sequencing of miRNAs and other low abundance and/or or short cellular RNAs. | 10-08-2015 |
| 20150275289 | Method for Accurate Sequencing of DNA - DNA is sequenced by (a) independently sequencing first and second strands of a dsDNA to obtain corresponding first and second sequences; and (b) combining the first and second sequences to generate a consensus sequence of the dsDNA. By independently sequencing first and second strands the error probability of the consensus sequence approximates a multiplication of those of the first and second sequences. | 10-01-2015 |
| 20150274757 | Branched Siloxanes And Methods For Synthesis - The present invention describes branched and functionalized siloxanes and methods for making such compounds. The compounds have a variety of uses. One preferred application is as novel planarizing material for lithography, in which case functionalized branched siloxane, such as an epoxy-modified branched siloxane is particularly useful. | 10-01-2015 |
| 20150273088 | ZAPRINAST ANALOGUES AS GLUTAMINASE INHIBITORS AND METHODS TO PREDICT RESPONSE THERETO - Zaprinast has been discovered to have activity against glutaminase 1, an important metabolic enzyme in selected cancers, for example, glutamine-dependent cancer types. Thus, glutamine-dependent cancer types, such as IDH1/2 gain-of-function mutant cancers or GLI1 overexpressing cancers, may be particularly sensitive to Zaprinast analogues. | 10-01-2015 |
| 20150266955 | DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis. | 09-24-2015 |
| 20150261090 | Ordering Block Copolymers - A method for ordering block copolymers including forming a first layer having a first preference mode; and providing a reactive agent in selected regions of the first layer that modifies the selected regions to a second preference mode, wherein the selected regions define other regions of the first layer retaining the first preference mode thereby forming an alignment layer for block copolymers. | 09-17-2015 |
| 20150250864 | ANTI-CANCER VACCINES - The present provides tumor-associated antigens and their use as vaccines for treating and limiting cancers in a patient. In specific aspects, HERV type K envelope proteins and peptides are provided. Such proteins and peptides can be used to elicit specific immune responses—both humoral and cellular—that target tumor cells expressing the HERV type K envelope protein. | 09-10-2015 |
| 20150240110 | Surface Treatments for Alignment of Block Copolymers - The present invention relates to a method the synthesis and utilization of random, cross-linked, substituted polystyrene copolymers as polymeric cross-linked surface treatments (PXSTs) to control the orientation of physical features of a block copolymer deposited over the first copolymer. Such methods have many uses including multiple applications in the semi-conductor industry including production of templates for nanoimprint lithography. | 08-27-2015 |
| 20150231357 | SYSTEMS AND METHODS FOR GAS MIXTURE DELIVERY TO HUMANS INSIDE AN MRI SCANNER - Systems and methods for delivery of gas mixtures to humans inside an MRI scanner, including while monitoring and recording physiological parameters. | 08-20-2015 |
| 20150226725 | BLOOD COAGULOMETER AND METHOD - An apparatus for determining blood clotting capacity comprises an actuator to cyclically move a member within a sample of blood received in a well in a tray and one of a deflection sensor and a position sensor to determine the position of the wetted member upon being acted upon by the actuator. The theoretical position of the wetted member, as determined using a known actuator force and wetted member physical data, is compared to the sensed deflection or position of the wetted member, and the resistance to movement of the wetted member caused by the blood is determined and correlated to a clotting capacity. | 08-13-2015 |
| 20150198614 | Beclin 1 Phosphorylation - Antibodies specific for human Beclin 1 protein phosphorylated Ser234, Ser295, Tyr229, Tyr233 or Try352 are useful in diagnosing diseases such as cancer and impaired autophagy. The invention further relates to human Beclin 1 mutated at Ser234, Ser295, Tyr229, Tyr233 or Try352 with a phospho-silencing residue and uses thereof. | 07-16-2015 |
| 20150197908 | SYSTEMS, APPARATUSES AND METHODS FOR ASSESSING SOIL HEAVE - A method of assessing soil heave includes providing a plurality of determined values of a shear modulus of soil, the determined values being values of the shear modulus of the soil at different times; and determining a change over time in the shear modulus of the soil, based on the plurality of determined values of the shear modulus of the soil. The soil may have been treated by adding a stabilizer to the soil. The soil may be hydrated. A system for assessing soil heave includes a bender element disposed in soil, for determining a change over time of a shear modulus of the soil, and a time domain reflectometer probe disposed in the soil, for determining a change over time of moisture content of the soil. The determined change over time of the shear modulus and the determined change over time of the moisture content are used to assess heaving of the soil. | 07-16-2015 |
| 20150196523 | ANTIMICROBIAL COMPOSITIONS COMPRISING GLYCERYL NITRATES - Provided are antimicrobial solutions comprising a glyceryl nitrate (e.g., glyeryl trinitrate) in combination with a chelator (e.g., citrate), a peroxide, a fatty acid, and/or an alcohol (e.g., ethanol). In various aspects these components may synergistically act to kill or reduce the growth of microbes, such as bacteria or fungi, present in a biofilm. | 07-16-2015 |
| 20150191987 | Underwater Noise Abatement Apparatus and Deployment System - A deployable underwater noise abatement system allowing packing and deploying an organized set of grouped resonators is disclosed. The system allows relatively compact storage and transportation of the noise abatement apparatus when not in use, then, when deployed, the apparatus can be lowered into the water and extended. | 07-09-2015 |
| 20150191546 | MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE - The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided. | 07-09-2015 |
| 20150182583 | METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES BY INHIBITING ENDOTHELIN RECEPTORS - Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothclin receptor A (ETA) and endothelin receptor B (ETB) may be administered to a subject to reduce tau production or accumulation, e.g., in astrocytes. The antagonist may be a dual ETA and ETB receptor antagonist. In some aspects, methods are provided for the treatment of chemo-brain, hypoxia, brain ischemia, surgical dementia, glioblastoma, or a traumatic brain injury (TBI). | 07-02-2015 |
| 20150178959 | BACKPROJECTION APPROACH FOR PHOTOACOUSTIC IMAGE RECONSTRUCTION - Various examples are provided for photoacoustic image reconstruction and processing utilizing a backprojection approach. In one example, among others, a method for producing an image with a photoacoustic imaging system includes scanning an object with a plurality of light beams, detecting a plurality of acoustic signals produced by the light beams, and generating a reconstructed image from the plurality of acoustic signals by filtered backprojection (FBP) that utilizes a weighted ramp filter. In another example, a system includes a plurality of acoustic detector units and a processing unit. The acoustic detector units can receive an acoustic wave and convert it to time dependent electrical signals. The processing unit can reconstruct an image of the subject from the time-dependent electrical signals by FBP that utilizes a weighted ramp filter. In another example, non-transitory computer readable medium stores a program that can cause a processing unit to reconstruct an image. | 06-25-2015 |
| 20150175660 | CONTROLLED MODULATION OF AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGENS - The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens. | 06-25-2015 |
| 20150157715 | Photokinetic Ocular Drug Delivery Methods and Apparatus - The present invention relates generally to transscleral, transcorneal, and transocular delivery of biologically active substances through the tissues, blood vessels and cellular membranes of the eyes of patients without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transscleral, transcorneal and transocular delivery of biologically active substances using pulsed incoherent light, and particularly the transcleral, transcorneal or transocular delivery of high molecular weight biologically active substances to a patient using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes of the eye of a subject using those compositions and methods. | 06-11-2015 |
| 20150157662 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS BY MODULATION OF DELTA-NP63 OR DCGR8 - The present invention generally concerns particular methods and compositions for generation of induced pluripotent stem cells. In particular aspects, induced pluripotent stem cells are generated from adult somatic cells following downregulation of a particular gene of interest. In some embodiments, induced pluripotent stem cells are generated from keratinocytes upon downregulation of ΔNp63 or DGCR8. | 06-11-2015 |
| 20150152504 | METHOD FOR DETERMINING COMPLETE RESPONSE TO ANTICANCER THERAPY - Methods for identifying patients with molecular or complete remission of colorectal cancer following therapy a fluorocytidine derivative and a COX-2 enzyme inhibitor by quantifying CD 133 expression levels. Methods for detecting cancer stem cells by quantifying serum CD 133 RNA levels are also provided. | 06-04-2015 |
| 20150147573 | NANOFIBER RIBBONS AND SHEETS AND FABRICATION AND APPLICATION THEREOF - The present invention is directed to nanofiber yarns, ribbons, and sheets; to methods of making said yarns, ribbons, and sheets; and to applications of said yarns, ribbons, and sheets. In some embodiments, the nanotube yarns, ribbons, and sheets comprise carbon nanotubes. Particularly, such carbon nanotube yarns of the present invention provide unique properties and property combinations such as extreme toughness, resistance to failure at knots, high electrical and thermal conductivities, high absorption of energy that occurs reversibly, up to 13% strain-to-failure compared with the few percent strain-to-failure of other fibers with similar toughness, very high resistance to creep, retention of strength even when heated in air at 450° C. for one hour, and very high radiation and UV resistance, even when irradiated in air. Furthermore these nanotube yarns can be spun as one micron diameter yarns and plied at will to make two-fold, four-fold, and higher fold yarns. Additional embodiments provide for the spinning of nanofiber sheets having arbitrarily large widths. In still additional embodiments, the present invention is directed to applications and devices that utilize and/or comprise the nanofiber yarns, ribbons, and sheets of the present invention. | 05-28-2015 |
| 20150126563 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 05-07-2015 |
| 20150125323 | FREE PISTON LINEAR MOTOR COMPRESSOR AND ASSOCIATED SYSTEMS OF OPERATION - A linear motor compressor including a compressor housing and a cylinder housing having a plurality of opposing compression chambers. A piston freely reciprocates within the cylinder housing using a linear electric motor. | 05-07-2015 |
| 20150123678 | PASSIVE WIRELESS SELF-RESONANT SENSOR - A sensor for detecting one or more materials includes a substrate, a passivation layer formed on the substrate, a self-resonant structure and a high surface area material disposed on the passivation layer. The self-resonant structure includes a planar spiral inductor and a plurality of planar interdigitated capacitor electrodes disposed within the passivation layer. The planar spiral inductor includes an electrically conductive trace formed on the substrate in a planar spiral pattern having at least two turns and an inter-winding space between parallel segments of the electrically conductive trace. The plurality of planar interdigitated capacitor electrodes are electrically connected to the electrically conductive trace of the planar spiral inductor and formed on the substrate within the inter-winding space of at least one outermost turn of the planar spiral inductor. The high surface area material includes a conformal polymer coating to increase a sensitivity to the one or more materials. | 05-07-2015 |
| 20150119947 | Method and Apparatus for Determining Cardiac Performance in a Patient - An apparatus for determining heart transplant rejection of a heart in a patient includes at least two electrodes adapted to be sewn into the heart that span the left ventricle. The apparatus includes a voltage generator adapted to be inserted in the patient which generates a voltage to the two electrodes and senses the resulting voltage from the two electrodes. A method for determining heart transplant rejection of a heart in a patient. A pacemaker for a patient (including bi-ventricular pacing and AICDs). The pacemaker includes an RV lead having four electrodes adapted to be inserted into the RV apex. The pacemaker includes a voltage generator which generates a voltage signal to the electrodes and senses the instantaneous voltage along the length of the RV and determines the real and imaginary components to remove the myocardial components of the septum and RV free wall to determine absolute RV blood volume. The pacemaker includes a battery connected to the voltage generator. The pacemaker includes a defibrillator connected to the battery. The pacemaker can also be a bi-ventricular pacemaker to restore RV and LV synchrony during contraction. A method for assisting a heart of a patient. | 04-30-2015 |
| 20150119730 | Method and Apparatus for Determining Cardiac Performance in a Patient with a Conductance Catheter - An apparatus for determining cardiac performance in the patient. The apparatus includes a conductance catheter for measuring conductance and blood volume in a heart chamber of the patient. The apparatus includes a processor for determining instantaneous volume of the ventricle by applying a non-linear relationship between the measured conductance and the volume of blood in the heart chamber to identify mechanical strength of the chamber. The processor is in communication with the conductance catheter. Methods for determining cardiac performance in a patient. Apparatuses for determining cardiac performance in a patient. | 04-30-2015 |
| 20150118181 | Concurrent Chemotherapy and Immunotherapy - The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine. | 04-30-2015 |
| 20150116548 | MAXIMIZING PERCEPTUAL QUALITY AND NATURALNESS OF CAPTURED IMAGES - A method, system and computer program product for improving the perceptual quality and naturalness of an image captured by an image acquisition device (e.g., digital camera). Statistical features of a scene being imaged by the image acquisition device are derived from models of natural images. These statistical features are measured and mapped onto the control parameters (e.g., exposure, ISO) of the digital acquisition device. By mapping these statistical features onto the control parameters, the perceptual quality and naturalness of the scene being imaged may be based on the values of these control parameters. As a result, these control parameters are modified to maximize the perceptual quality and naturalness of the scene being imaged. After modification of these control parameters, the image is captured by the image acquisition device. In this manner, the perceptual quality and naturalness of the image captured by the image acquisition device is improved. | 04-30-2015 |
| 20150110848 | ADSORPTION OF PROTEINS ON CONDUCTING SURFACES UPON APPLICATION OF EXTERNAL POTENTIAL - The present invention provides methods for adsorbing a protein onto a conductive solid substrate, comprising the application of an external potential to the solid substrate greater than +500 mV vs. the Ag/AgCl/Cl | 04-23-2015 |
| 20150105301 | ALKOXY CARBOXYLATE SURFACTANTS - Provided herein are inter alia novel compositions and methods having application in a variety of fields including the field of enhanced oil recovery, the cleaning industry as well as groundwater remediation. In particular, the alkoxy carboxylate compounds and mixtures thereof presented herein can be used, inter alia, for the recovery of a large range of crude oil compositions from challenging reservoirs. | 04-16-2015 |
| 20150100599 | User-Powered Recommendation System - Recommendation systems are widely used in Internet applications. In current recommendation systems, users only play a passive role and have limited control over the recommendation generation process. As a result, there is often considerable mismatch between the recommendations made by these systems and the actual user interests, which are fine-grained and constantly evolving. With a user-powered distributed recommendation architecture, individual users can flexibly define fine-grained communities of interest in a declarative fashion and obtain recommendations accurately tailored to their interests by aggregating opinions of users in such communities. By combining a progressive sampling technique with data perturbation methods, the recommendation system is both scalable and privacy-preserving. | 04-09-2015 |
| 20150080878 | DEVICE AND METHOD FOR TISSUE REMOVAL - Exemplary embodiments are directed to devices and methods for tissue removal. Exemplary embodiments can be configured for mechanical dissection as well as suction to grasp, resect and collect all or part of a target tissue. Exemplary embodiments may also comprise elements for cauterization of tissue and coagulation of blood vessels. | 03-19-2015 |
| 20150073033 | BIOMARKERS FOR CANCER CHARACTERIZATION AND TREATMENT - Composition and methods for characterizing cancer cells by determining a marker of PKM2 activity. For example, methods are provided for predicting a patient response to a NF-κB, PKCε, PKM2, MEK/ERK, Pin1 or Src inhibitor therapy. Methods for treating patients with such therapies are likewise provided. Phosphorylation selective β-catenin, MLC2, histone H3, Bub3, and PKM2-binding antibodies are also provided. | 03-12-2015 |
| 20150064709 | MODULATING GENE EXPRESSION WITH agRNA AND GAPMERS TARGETING ANTISENSE TRANSCRIPTS - Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene. | 03-05-2015 |
| 20150064160 | ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS - Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids. | 03-05-2015 |
| 20150064159 | ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES - Methods and compositions relating to the engineering of an improved protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids. | 03-05-2015 |
| 20150064154 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. | 03-05-2015 |
| 20150060957 | THREE-DIMENSIONAL GATE-WRAP-AROUND FIELD-EFFECT TRANSISTOR - A three-dimensional Gate-Wrap-Around Field-Effect Transistor (GWAFET). The GWAFET includes a substrate of III-V semiconductor material. The GWAFET further includes one or more channel layers with a gate wrapped around these one or more channel layers. Additionally, the GWAFET includes a barrier layer residing on the top channel layer with a layer of doped III-V semiconductor material residing on each end of the barrier layer. A source and drain contact are connected to the layer of doped III-V semiconductor material as well as to the multiple channels in the embodiment with the GWAFET including multiple channel layers. By having such a structure, integration density is improved. Furthermore, electrostatic control is improved due to gate coupling, which helps reduce standby power consumption. Furthermore, by using III-V semiconductor material as opposed to silicon, the current drive capacity is improved. | 03-05-2015 |
| 20150054135 | SELF-ALIGNED MASKS AND METHODS OF USE - The disclosure relates to a method for forming a nanoscale structure by forming a pattern on a selectively etched layer located on top of a substrate using lithography, wherein the pattern results a gap having sidewalls, performing RIE on the gap having sidewalls, wherein RIE results in the formation of a self-aligned mask on the bottom wall of the gap with unprotected regions on the bottom wall of the gap near the junctions with the sidewalls, and wet etching the gap having a self-aligned mask and unprotected regions to remove the substrate under the unprotected regions to form a nanoscale structure in the substrate. | 02-26-2015 |
| 20150053929 | VERTICAL III-V NANOWIRE FIELD-EFFECT TRANSISTOR USING NANOSPHERE LITHOGRAPHY - A vertical III-V nanowire Field-Effect Transistor (FET). The FET includes multiple nanowires or nanopillars directly connected to a drain contact, where each of the nanopillars includes a channel of undoped III-V semiconductor material. The FET further includes a gate dielectric layer surrounding the plurality of nanopillars and a gate contact disposed on a gate metal which is connected to the gate dielectric layer. Additionally, the FET includes a substrate of doped III-V semiconductor material connected to the nanopillars via a layer of doped III-V semiconductor material. In addition, the FET contains a source contact directly connected to the bottom of the substrate. By having such a structure, electrostatic control and integration density is improved. Furthermore, by using III-V materials as opposed to silicon, the current drive capacity is improved. Additionally, the FET is fabricated using nanosphere lithography which is less costly than the conventional photo lithography process. | 02-26-2015 |
| 20150048681 | MULTIPLE-INPUT ISOLATED PUSH-PULL CONNECTED POWER CONVERTERS - A multiple-input power converter transferring energy from multiple input sources to a load. The multiple-input power converter utilizes a push-pull converter that isolates loads from sources by a transformer in the output rectifier stage. The isolation increases the safety of the system and provides a wider range of sources-to-load voltage transfer ratios. Furthermore, the multiple-input power converter utilizes a lower number of components in comparison to previously designed multiple-input power converter topologies as well as has a lower control circuit implementation cost when compared to previously designed soft-switching multiple-input power converters. | 02-19-2015 |
| 20150047846 | METHOD OF IMPROVING HYDRAULIC FRACTURING BY DECREASING FORMATION TEMPERATURE - A method for producing fractures in a formation to release hydrocarbons (such as a hydrocarbon gas or liquid) from the formation is disclosed. The method comprises reducing the in-situ temperature at a location in a formation having a first temperature by contacting the location with a first fluid and contacting the location with a fracturing fluid to produce fractures in the formation while the location is at a second temperature below the first temperature to release hydrocarbons from the formation. The method can include using an endothermic process to reduce the temperature at the location in the formation. | 02-19-2015 |
| 20150034077 | PULSE DRUG NEBULIZATION SYSTEM, FORMULATIONS THEREFORE, AND METHODS OF USE - Liquid nebulizer apparatus, systems, and formulation compositions, as well as systems for the nebulized, aerosol delivery of such compositions, for the administration and insufflation of medicinal aerosols into the pulmonary system of a mammal are described. The nebulizing apparatus and system can effectively aerosolize a variety of viscosities of medicinal liquid drug carriers, including those made up of oil, water, or emulsions of oil and water. Drugs dissolved or suspended in the compositions and formulations described and adapted for use herein are not damaged or denatured by the nebulization process when the nebulizer described is used. Further, the nebulization system itself can be adapted for use with both mechanically assisted pulmonary ventilation systems as well as hand-held inhalers and nose/mouth face masks for use in pulmonary drug delivery. | 02-05-2015 |
| 20150024425 | Apparatuses And Methods For Forming Wounds In Cell Layers - In one embodiment, an apparatus for forming wounds in cell layers includes a base that includes a guide track, and a sliding member adapted to fit within the guide track, the sliding member including a scratching element holder adapted to secure a scratching element in a position in which it contacts a cell layer, wherein the sliding member is further adapted to slide along the guide track to drag the scratching element through the cell layer. | 01-22-2015 |
| 20150017651 | PERSONALIZED MEDICINE FOR THE PREDICTION OF THERAPY TARGETING THE HEDGEHOG PATHWAY - Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status. | 01-15-2015 |
| 20140378529 | COLLATERAL GENE INACTIVATION BIOMARKERS AND TARGETS FOR CANCER THERAPY - Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor. | 12-25-2014 |
| 20140377339 | TUSC2 THERAPIES - A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. | 12-25-2014 |
| 20140377294 | ADENOVIRUSES EXPRESSING HETEROLOGOUS TUMOR-ASSOCIATED ANTIGENS - The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface. | 12-25-2014 |
| 20140377221 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION - The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy. | 12-25-2014 |
| 20140377181 | MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF - The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules. | 12-25-2014 |
| 20140371101 | PARP Substrates and Biomarkers - PARylated proteins are enriched by treating cell lysates comprising PARylated proteins and DNA/RNA with an endonuclease that cleaves the DNA/RNA but not the PAR; and separating the PARylated proteins from the cleaved DNA/RNA. PARylation sites are labeled by eluting PARylated proteins from a PAR-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels PARylation sites of the proteins. Specific binding agents are identified by screening compounds for specific binding to a PARylated protein disclosed herein; and identifying one of the compounds as a specific binder of the protein. Antibodies which specifically bind PARylation sites are also disclosed. | 12-18-2014 |
| 20140364347 | DI-FUNCTIONAL ANIONIC SURFACTANTS FOR ENHANCED OIL RECOVERY - The present invention describes the synthesis and use of cleavable di-functional anionic surfactants for enhanced oil recovery applications and/or the use of sacrificial surfactants. | 12-11-2014 |
| 20140363376 | MOLECULAR DESIGN TOWARD DUAL-MODALITY PROBES FOR RADIOISOTOPE-BASED IMAGING (PET OR SPECT) AND MRI - In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof. | 12-11-2014 |
| 20140358229 | Medical Devices, Apparatuses, Systems, and Methods With Magnetic Shielding - Embodiments of apparatuses, and methods and systems including apparatuses, configured to be magnetically coupled to a medical device within a body cavity of a patient. Some embodiments include one or more elements comprising at least one of a magnetically-attractive and magnetically-chargeable material; and a bumper extending around the one or more elements and configured to reduce the strength of a magnetic field of the one or more elements. | 12-04-2014 |
| 20140350645 | Altering Temperature in a Mammalian Body - The present application relates to systems and methods for altering temperature in a mammalian body. Optionally, the systems and methods can be used to lower or raise core body temperature of a mammalian subject. Optionally, the systems and methods can be used to lower or raise the temperature of glabrous skin of a mammalian subject. | 11-27-2014 |
| 20140349860 | IDENTIFYING PEPTIDES AT THE SINGLE MOLECULE LEVEL - The present invention relates to methods for identifying amino acids in peptides. In one embodiment, the present invention contemplates labeling the N-terminal amino acid with a first label and labeling an internal amino acid with a second label. In some embodiments, the labels are fluorescent labels. In other embodiments, the internal amino acid is lysine. In other embodiments, amino acids in peptides are identified based on the fluorescent signature for each peptide at the single molecule level. | 11-27-2014 |
| 20140349402 | CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA - The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example. | 11-27-2014 |
| 20140348902 | TCL1 PEPTIDES FOR IMMUNOTHERAPY - Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided. | 11-27-2014 |
| 20140342291 | Novel Dual-Tone Resist Formulations And Methods - Dual tone photoresist formulations comprising a photoacid generator are described and employed in fabrication techniques, including methods of making structures on substrates, and more particularly, methods of making electronic devices (e.g. transistors and the like) on flexible substrates wherein two patterns are formed simultaneously in one layer of photoresist. | 11-20-2014 |
| 20140335549 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 11-13-2014 |
| 20140333197 | Compositions of Mercury Isotopes for Lighting - Described herein is a mercury sample that has an isotopic composition that differs from the naturally occurring distribution of isotopes. In various configurations of an isotopically tailored mercury sample, the fraction of one or more isotopes is increased or decreased with respect to the natural fraction(s). A example of a lighting device comprises an envelope, a buffer gas enclosed within the envelope, a isotopically tailored sample of mercury vapor, and a current injection mechanism configured to excite the mercury vapor to emit light. In various configurations, the lighting device emits radiation at a wavelength of 254 nm and/or at a wavelength of 185 nm. In various configurations, the lighting device envelope includes a fluorescent coating that is excited by ultraviolet (UV) light emitted by the mercury vapor. In various configurations, the lighting device provides improved efficiency as compared to lamps employing mercury with a naturally occurring isotope distribution. | 11-13-2014 |
| 20140329901 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES - The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines. | 11-06-2014 |
| 20140329287 | COMPOSITIONS AND METHODS FOR LIPID PRODUCTION - Described herein, inter alia, are compositions, oleagnious organisms, and methods useful for producing lipids, lipid precursors, and/or oleochemicals. | 11-06-2014 |
| 20140322303 | LIPOSOMAL CURCUMIN FOR TREATMENT OF DISEASES - The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic. | 10-30-2014 |
| 20140319026 | SHORT CHAIN ALKYLAMINE ALKOXYLATE COMPOSITIONS - Provided herein are, inter alia, compositions including a surfactant and a novel compound useful in enhanced oil recovery. The compositions and methods provided herein may be particularly useful for oil recovery under a broad range of reservoir conditions (e.g. high to low temperatures, high to low salinity, highly viscous oils). | 10-30-2014 |
